Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.

This study found that continuous use of loop diuretics may double the rate of bone loss in elderly men compared to intermittent or non-use.

In this study, patients with varying severities of acne, seborrhoea, and hirsutism responded differently to Cyproteronacetate and Ethinyloestradiol treatment, with improvement rates dependent on symptom severity and treatment duration.

This study found that both finasteride and a regimen of cyproterone acetate plus ethinyl estradiol effectively reduced hirsutism in women, with similar results despite differing hormonal effects.

This article discusses the considerations and challenges surrounding a proposed large-scale trial on testosterone-replacement therapy in older men and reports no new results.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.

This article reviews the role of testosterone in sexual health, supporting Testosterone Replacement Therapy as an effective treatment for Hypoactive Sexual Desire Disorder in postmenopausal women, though more research is needed on its long-term effects and applicability to premenopausal women.

This abstract reports preliminary data on the antidepressant reboxetine, noted for its different mode of action, discussed at a major psychiatry conference; it provides no new research findings.

This study found that 54% of participants with androgenetic alopecia using Ricapil® showed clinical signs of hair follicle reactivation and initial hair regrowth over three months.

This study found that tribuloside, a flavonoid from Tribulus terrestris L., enhances melanin production in human melanocytes, zebrafish, and human skin samples without causing toxicity, potentially through inhibiting PDE to increase cAMP levels and promote the melanin biosynthesis pathway.

This publication reviews the World Professional Association for Transgender Health's Standards of Care for supporting transgender and gender nonconforming people, with adjustments needed for diverse global contexts and no new clinical results.

This study found that the prevalence of polycystic ovary syndrome was 6.5% in a minimally biased sample of Caucasian women from Spain.

This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.

This study suggests that increased use of anticancer drugs from 2004 to 2008 has led to higher environmental release, necessitating expanded monitoring and research on their ecotoxicological impacts.

This study found a 6.5% prevalence of polycystic ovary syndrome among a population of Caucasian women in Spain, based on specific endocrine criteria.

This review discusses the effects of hormonal treatments on the physical and mental health of transgender individuals, reporting significant reductions in mental health issues following treatment, but calls for more research on long-term and nonbinary outcomes.

This article reviews drug-induced hair changes, highlighting that while many drugs are occasionally linked to hair loss, this connection has been conclusively established for only a few, and such hair loss is typically reversible.

This article outlines the clinical features, evaluation, and treatment strategies for androgen excess in polycystic ovary syndrome, highlighting important diagnostic and management approaches but reporting no new research results.

This review discusses the dermatologic features of PCOS as potential early indicators of the syndrome and notes that treatment of these conditions may enhance quality of life and psychological well-being, but it reports no new clinical results.

This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.

This study utilized a sequence-structure alignment approach to improve the characterization of Class A Rhodopsin GPCR superfamily, including orphan and unclassified receptors, through evolutionary analysis.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

This review highlights the need for tailored hormonal treatment strategies for non-binary transgender individuals, emphasizing personalized care to enhance psychological well-being and quality of life.

This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.